2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|March 15, 2015
- Pharmaceutical Technology-03-15-2015
- Volume 2015 eBook
- Issue 1
Boosting Solubility in Lipid-Based Formulations
Author(s)Agnes Shanley
Ionic liquid technologies offer a new way to improve bioavailability.
Advertisement
Ionic liquid technologies offer a new way to improve bioavailability and potentially shrink patients’ daily dose requirements. Keith Hutchison, PhD, senior vice-president of R&D for Capsugel, describes the technology.
Download
Articles in this issue
over 11 years ago
Advances in Tabletingover 11 years ago
Assessing and Improving the Palatability of Pharmaceuticalsover 11 years ago
Analytical Techniques for Oral Solid Dosage Formulationover 11 years ago
Simplify Formulation With PATover 11 years ago
Innovations in Solid Dosage EquipmentAdvertisement
Related to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement